NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Wall Street closed mostly lower on Tuesday with the Dow Jones posting its fourth consecutive daily gain, however broader market dropped over trade related concerns. The Dow Jones Industrial Average gained 0.46 percent to close at 26,773.94, its 14th record close for 2018 fueled by gains in Intel Corp and Caterpillar Inc. The S&P 500 Index shed 0.04 percent to close at 2,923.43, while the Nasdaq Composite Index dropped 0.47 percent to close at 7,999.55.
“U.S. stocks are mixed with the global markets looking past yesterday’s trade agreement with Canada, as the U.S./China relationship remains contentious,” said Charles Schwab analysts. “Records in the U.S. stock market do not, in our view, mean that investors should get more aggressive in their investment stance. High expectations, elevated investor sentiment, trade disputes, and the possibility of a monetary mistake lead us to take a more cautious stance,” said the analysts.
RDI Initiates Coverage on:
Flex Pharma, Inc.
Clovis Oncology, Inc.
Flex Pharma's stock jumped 22.58% Tuesday, to close the day at $0.57. The stock recorded a trading volume of 4,422,641 shares, which was above its three months average volume of 320,453 shares. In the last year, Flex Pharma's shares have traded in a range of 0.39 - 8.98. The share price has gained 46.15% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.49 is below its 200-day moving average of $2.55. Shares of Flex Pharma have gained roughly 15.15 percent in the past month and are down 83.67 percent year-to-date.
Access RDI's Flex Pharma, Inc. Research Report at:
On Tuesday, shares of Clovis Oncology recorded a trading volume of 5,794,991 shares, which was above the three months average volume of 958,353 shares. The stock ended the day 7.72% higher at $31.39. The share price has fallen 63.61% from its 52 week high with a 52 week trading range of 28.70 - 86.26. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $33.90 is below its 200-day moving average of $44.50. Shares of Clovis Oncology have fallen roughly 12.20 percent in the past month and are down 53.84 percent year-to-date.
Access RDI's Clovis Oncology, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.